Ligand Pharmaceuticals Incorporated
- LGND
- NASDAQ
- Biotechnology
- Pharmaceutical Technology Licensing
- Drug Discovery Enabling
$297.28
Today +0.59%Quote Oct 19, 2026, 08:00 PM UTC
+4.86%over the last month
Max drawdown −6.6%From 1-month high −5.4%3 months −2.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions.
Where the money comes from
Q2 2026 revenue $118.4M
- Royalty$48.0M40.6%
- Intangible Royalty Assets$37.4M31.5%
- Financial Royalty Assets$10.7M9.0%
- Material Sales, Captisol$8.0M6.7%
- Kyprolis$7.0M5.9%
- Rylaze$3.2M2.7%
- Contract Revenue$2.7M2.3%
- Teriparatide Injection$1.5M1.2%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
47
Market value
$5.93B
Quote Oct 19
Floor
$287.93
3.1% below price
Resistance
$296.80
Price is above this level
Price vs analyst targets
18 analysts
Lowest target
$326.00Highest target
$358.00
$326.00Highest target
$358.00
- Price $297.28
- Average target $339.43
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 14% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about LGNDPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free